Journey Medical Corporation Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

LICENSES ACQUIRED (Details)

v3.23.1

LICENSES ACQUIRED (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	Nov. 16, 2021 $ / shares shares	Jun. 29, 2021 USD ($)	Dec. 31, 2022 USD ($) item	Dec. 31, 2021 USD ($)
LICENSES/PRODUCTS ACQUIRED
Payments to Acquire Productive Assets			$ 20,000
Research and development - licenses acquired				$ 13,819
License development cost			13,000
Contingent Payment Derivative
LICENSES/PRODUCTS ACQUIRED
Unregistered shares issued \| shares	545,131
Volume weighted average price per share related to shares issued \| $ / shares	$ 9.1721
Number of days for calculating weighted average price	15 days
D F D Agreement
LICENSES/PRODUCTS ACQUIRED
Amount payable		$ 10,000		$ 10,000
Research and development - licenses acquired		$ 3,800
D F D Agreement \| Contingent Payment Derivative
LICENSES/PRODUCTS ACQUIRED
Value of shares to be issued			5,000
Unregistered shares issued \| shares	545,131
Cash payment			$ 5,000
Volume weighted average price per share related to shares issued \| $ / shares	$ 9.1721
Number of days for calculating weighted average price			15 days
Number of payments \| item			1
D F D Agreement \| Minimum
LICENSES/PRODUCTS ACQUIRED
Percentage of royalties payable on net sales		10.00%
D F D Agreement \| Minimum \| Contingent Payment Derivative
LICENSES/PRODUCTS ACQUIRED
Market Capitalization			$ 150,000
D F D Agreement \| Maximum
LICENSES/PRODUCTS ACQUIRED
Threshold additional contingent regulatory and commercial milestone payments payable		$ 158,000
Percentage of royalties payable on net sales		15.00%

- Definition

The cash payment for contingent consideration.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementContingentConsiderationCashPayment
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of payments to be made on contingent consideration in license, collaboration and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementContingentConsiderationNumberOfPayments
Namespace Prefix:	derm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The value of shares to be issued for payment of contingent consideration.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementContingentConsiderationValueOfSharesToBeIssued
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The threshold market capitalization upon the completion of an IPO for contingent payment associated with IPO is deemed to be achieved.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementContingentPaymentThresholdMarketCapitalization
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of royalties payable on net sales under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementPercentageOfRoyaltiesPayableOnNetSales
Namespace Prefix:	derm_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of trading days for calculating volume weighted average price.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementPeriodOfTradingDaysForCalculatingWeightedAveragePrice
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Threshold additional contingent regulatory and commercial milestone payments payable under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementThresholdAdditionalContingentRegulatoryAndCommercialMilestonePaymentsPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Total amount payable under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementTotalAmountPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of research and development expense related to licenses acquired.

+ References

No definition available.

+ Details

Name:	derm_ResearchAndDevelopmentExpenseRelatedToLicensesAcquired
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total number of unregistered common shares of an entity that have been sold or granted to shareholders.

+ References

No definition available.

+ Details

Name:	derm_UnregisteredCommonStockSharesIssued
Namespace Prefix:	derm_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Volume weighted average price per share related to shares issued.

+ References

No definition available.

+ Details

Name:	derm_VolumeWeightedAveragePriceRelatedToSharesIssued
Namespace Prefix:	derm_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=derm_ContingentPaymentDerivativeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=derm_DFDAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: